ImmunoACT
ImmunoACT is an India-based cell and gene therapy company developing and commercializing NexCAR19, India's first approved CAR-T therapy for relapsed/refractory B-cell malignancies. It manufactures autologous CD19-directed CAR-T products using proprietary humanized constructs, serving cancer hospitals across India and select African markets via Cipla.
- Company typePrivate
- Founded2018
- HeadquartersMumbai, India
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What ImmunoACT does
ImmunoACT (legally Immunoadoptive Cell Therapy Private Limited) is an advanced cell and gene therapy company headquartered in Navi Mumbai, India, founded in 2018 as a spin-off from IIT Bombay. The company develops and manufactures autologous CAR-T cell therapies, with its core product NexCAR19 (talicabtagene autoleucel) being India's first and only approved CAR-T therapy, indicated for relapsed/refractory B-cell Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia. NexCAR19 features a proprietary humanized scFv CAR construct targeting CD19 with a 4-1BB co-stimulatory domain, achieving a 98% manufacturing success rate and approximately 20-day vein-to-vein time, compared to 40+ days for global CAR-T programs.
The company's technology platform spans end-to-end capabilities: in-house plasmid DNA manufacturing, proprietary lentiviral vector production (~1.2 × 10^10 TU per batch), and GMP-certified cell engineering facilities. ImmunoACT has treated over 600 patients across 130+ authorized cancer treatment centers in India and 60+ international patients from 24 countries. NexCAR19 is priced at approximately Rs 35-40 lakh per infusion (~USD 35,000), roughly one-tenth the cost of imported CAR-T alternatives. Revenue derives from direct commercial sales of the single-dose therapy in India and from an exclusive license and supply agreement with Cipla for commercialization in South Africa, Algeria, and Morocco (effective January 2026). Patient access is supported through the Hope Initiative, which includes 0% interest EMI financing up to Rs 10 lakhs and value-based pricing with outcome-linked rebates.
ImmunoACT is privately held, with Laurus Labs as the largest institutional investor at a 33.86% stake following investments in November 2021 (~Rs 46 crore for 26.62%) and May 2023 (Rs 80 crore for an additional 7.24%). The pipeline includes HCAR2 (BCMA-directed CAR-T for multiple myeloma in Phase I), HCAR3 (GD2-directed for solid tumors, expected 2027), HCAR4 (gastric/GEJ cancer, expected 2028), and TriCAR (multi-target CD19/CD20/CD22). Scientific advisory includes Dr. Carl June, the pioneer of the world's first CAR-T therapy.
ImmunoACT firmographics
Firmographics- Name
- ImmunoACT
- Legal name
- Immunoadoptive Cell Therapy Private Limited
- Website
- https://immunoact.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- ImmunoACT is an India-based cell and gene therapy company developing and commercializing NexCAR19, India's first approved CAR-T therapy for relapsed/refractory B-cell malignancies. It manufactures autologous CD19-directed CAR-T products using proprietary humanized constructs, serving cancer hospitals across India and select African markets via Cipla.
- Ownership category
- akta.pro rank
ImmunoACT industry classification
Industry- Product category
- Cell and Gene Therapy (CAR-T Cell Therapy)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)
Keywords
Where ImmunoACT is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
ImmunoACT business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- CAR-T Cell Therapy Sales: Direct commercial sales of NexCAR19 (talicabtagene autoleucel) to patients treated at authorized hospital centers in India. Revenue generated from single-dose infusions at approximately Rs 35-40 lakh per treatment.
- Licensing and Supply (Africa): Exclusive license and supply agreement with Cipla for commercialization in South Africa, Algeria, and Morocco. ImmunoACT manufactures in India while Cipla commercializes in licensed territories, generating licensing/royalty revenue.
- Patient Support Programs: Partnership with Mango Sciences for bridge financing (0% interest EMI plans up to Rs 10 lakhs) and value-based pricing rebates. While not direct revenue, these programs expand patient access and drive treatment adoption.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | NexCAR19 single infusion treatment |
Go-to-market motion4 records
Distribution channels3 records
Marketing channels7 records
ImmunoACT product offering
Product offeringCore offering
ImmunoACT manufactures and commercializes NexCAR19 (Talicabtagene autoleucel), an autologous CD19-directed CAR-T cell therapy for patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia. The therapy is produced via a proprietary humanized scFv CAR construct using in-house lentiviral vector and plasmid DNA manufacturing platforms, delivered as a single-dose infusion at approximately Rs 35–40 lakh through 130+ authorized treatment centers in India and via Cipla in Africa.
Product overview
ImmunoACT is a fully integrated CAR-T cell therapy company developing and manufacturing accessible, affordable gene-modified cell therapies. The core product portfolio centers on NexCAR19 (talicabtagene autoleucel), India's first approved CAR-T therapy for relapsed/refractory B-cell malignancies, supported by proprietary lentiviral vector and plasmid DNA manufacturing platforms. The pipeline expands into solid tumors (HCAR3 for glioblastoma/neuroblastoma, HCAR4 for gastric cancer), hematological malignancies (HCAR2 for multiple myeloma), and multi-target approaches (TriCAR). Patient access is enabled through The Hope Initiative (bridge financing, value-based pricing), ACT.360 monitoring platform, and the ImmunoACT Foundation philanthropic program.
Differentiator
Problem solved
Functional benefit
Products and services
- NexCAR19 (Talicabtagene autoleucel) India's first approved autologous CD19-directed CAR-T cell therapy for adults and pediatric patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma (including DLBCL, PMBCL, FL, MCL, MZL, HGBL) and B-cell Acute Lymphoblastic Leukemia. The therapy uses a second-generation humanized CAR construct with a 4-1BB co-stimulatory domain, CD8α transmembrane domain, and CD3ζ signaling domain. It is administered as a single-dose infusion manufactured in approximately 18-20 days from apheresis to infusion with 98% manufacturing success rate.
- HCAR2 (BCMA-directed CAR-T) BCMA-directed CAR-T cell therapy candidate for multiple myeloma. Currently in multi-centre Phase I clinical trial demonstrating manufacturing feasibility, safety, and activity. Developed as ImmunoACT's second CAR-T pipeline product targeting a hematological malignancy beyond CD19.
- HCAR3 (GD2-directed CAR-T)
Quantifiable outcome
- 90% remission rate with NexCAR19 treatment
- +8 more outcomes
Companies that use ImmunoACT
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
ImmunoACT technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
ImmunoACT partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- CiplacoreExclusive license and supply agreement with Cipla (via Medpro Pharmaceutica) to commercialize talicabtagene autoleucel in South Africa, Algeria, and Morocco. ImmunoACT manufactures product in India while Cipla leads commercialization in licensed African territories.
- Mango SciencescorePartnership to launch world's first bridge financing plan and value-based offering for CAR-T therapy in India. Mango Sciences provides 0% interest EMI financing up to Rs 10 lakhs and value-based pricing with outcome-linked rebates.
- Tata Memorial Hospital / Tata Memorial CentrecoreClinical collaboration for development and first-in-human dosing of NexCAR19. Tata Memorial Hospital conducted Phase I/II clinical trials and continues as key treatment center.
- IIT Bombay / SINEcoreImmunoACT was established in 2018 as a spin-off from IIT Bombay's Biosciences & Bioengineering department, incubated at SINE (Society for Innovation and Entrepreneurship). Research began in 2013.
- Carl JuneminorDr. Carl June (Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania) serves as advisor. Pioneer of world's first CAR-T cell therapy.
- Avery D PoseyminorDr. Avery D Posey (Assistant Professor, Parker Institute for Cancer Immunotherapy, UPenn) - Expert on CAR-T for solid tumors.
- Gaurav NarulaminorDr. Gaurav Narula (Professor, Tata Memorial Hospital) - Leading first CAR-T trial of pediatric B-ALL in India.
- Sattva NeelapuminorDr. Sattva Neelapu (MD Anderson Cancer Center) - Pioneer in clinical studies of CAR-T cell therapy.
- Nirali ShahminorDr. Nirali Shah (Head of Hematologic Malignancies Section, Pediatric Oncology Branch at NCI, NIH) - Expert in CAR-T for pediatric leukemia.
Scale indicators11 records
Recent moves9 records
Expansion highlights6 records
ImmunoACT competitors and assessment
Company assessmentOthers
- Laurus Labs: Strategic investor with 33.86% ownership and manufacturing-partner role for ImmunoACT. Comparable as a major Indian pharmaceutical company with overlapping API/biologics manufacturing capabilities and as the closest equity stakeholder, making it the most direct strategic counterparty.
Direct peers
- JW Therapeutics: China-headquartered CAR-T company with Carteyva (relmacabtagene autoleucel), an autologous CD19 CAR-T. Directly comparable in product profile, autologous manufacturing model, and emerging-market commercialization approach.
- Carsgen Therapeutics: China-based CAR-T developer with approved autologous products (e.g., Carteyva for R/R LBCL) — closely comparable in being a non-Big-Pharma CAR-T company that has built proprietary manufacturing and clinical-trial capabilities in an emerging market. Most relevant emerging-market peer.
Emerging players
- Allogene Therapeutics: US-listed allogeneic ("off-the-shelf") CAR-T developer with multiple candidates in hematologic and solid tumors. Adjacent peer with overlapping lentiviral platform technology and overlapping indications (CD19, BCMA); relevant comparator for ImmunoACT's pipeline direction.
- Bluebird Bio: Gene and cell therapy company focused on autologous lentivirally-engineered therapies, including Abecma (now BMS) and Lyfgenia. Comparable in lentiviral manufacturing, autologous cell-therapy focus, and similar commercial/scale challenges in the cell-therapy space.
- CRISPR Therapeutics: Developer of Casgevy (exa-cel), the first approved gene-edited cell therapy, with a CAR-T pipeline (CD19, CD70). Comparable as a next-generation cell therapy innovator; relevant for technology-platform and indication-overlap benchmarking.
Broad incumbents
- Gilead Sciences (Kite Pharma): Markets Yescarta and Tecartus, leading autologous CD19 CAR-T therapies globally. Highly comparable product profile (autologous CD19 CAR-T for R/R B-NHL/B-ALL) and the broadest commercial CAR-T infrastructure worldwide — the most likely global competitor to expand into India.
- Janssen (Johnson & Johnson): Markets Carvykti (cilta-cel), a leading BCMA-directed CAR-T for multiple myeloma — directly comparable to ImmunoACT's HCAR2 in target and indication. As a top-3 global CAR-T player, Janssen represents a relevant incumbent peer for ImmunoACT's BCMA program direction.
- Bristol Myers Squibb: Markets Breyanzi (CD19 CAR-T) and Abecma (BCMA CAR-T) — directly comparable to both ImmunoACT's commercial CD19 program and its in-Phase-I HCAR2 (BCMA) program. Represents a potential competitor and a natural out-licensing/out-licensing acquirer of CAR-T assets.
- Novartis: Global pharma with Kymriah, the first FDA-approved CAR-T therapy (CD19). Directly comparable to ImmunoACT's NexCAR19 in mechanism (CD19 CAR-T) and indication (B-cell malignancies), with deep commercial reach into India's top cancer centers via established oncology field forces.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
ImmunoACT social profiles
Digital presenceImmunoACT compliance and trust
Trust signalCompliance2 records
ImmunoACT financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmunoACT leadership team
Management profileNumber of profiles
Profiles1 record
ImmunoACT funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmunoACT M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmunoACT
What does ImmunoACT do?
ImmunoACT manufactures and commercializes NexCAR19 (Talicabtagene autoleucel), an autologous CD19-directed CAR-T cell therapy for patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia. The therapy is produced via a proprietary humanized scFv CAR construct using in-house lentiviral vector and plasmid DNA manufacturing platforms, delivered as a single-dose infusion at approximately Rs 35–40 lakh through 130+ authorized treatment centers in India and via Cipla in Africa.
Is ImmunoACT a public or private company?
ImmunoACT is a private company. It is classified as venture growth investor backed and is currently operating.
When was ImmunoACT founded?
ImmunoACT was founded in 2018. It employs 101 to 250 people.
Where is ImmunoACT based?
ImmunoACT is headquartered in Mumbai, India, in the Asia region.
How does ImmunoACT make money?
Three revenue lines are on record. CAR-T Cell Therapy Sales are the primary driver. The others are licensing and Supply (Africa) and patient Support Programs.
Who are ImmunoACT's main competitors?
Laurus Labs is listed as an others. Direct peers are JW Therapeutics and Carsgen Therapeutics. Emerging players are Allogene Therapeutics, Bluebird Bio and CRISPR Therapeutics. Broad incumbents are Gilead Sciences (Kite Pharma), Janssen (Johnson & Johnson), Bristol Myers Squibb and Novartis.
Does ImmunoACT have an API?
No public API is recorded for ImmunoACT.
What industry is ImmunoACT in?
ImmunoACT's product category is Cell and Gene Therapy (CAR-T Cell Therapy). Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.